Humatrope Für Pen (Somatropin)

Humatrope Für Pen is indicated for patients who have a documented deficiency of endogenous growth hormone or related conditions that affect linear growth, body composition, or metabolic function, and it may be prescribed by specialists in endocrinology.

• Growth hormone deficiency in children and adults, confirmed by stimulation testing
• Turner syndrome to improve height velocity in girls with confirmed short stature
• Chronic renal insufficiency associated growth failure, when renal disease limits normal growth
• Prader‑Willi syndrome to support growth and body composition
• Idiopathic short stature in children who have not responded to other therapies
• Adult growth hormone deficiency secondary to pituitary or hypothalamic disease

• Somatropin in Humatrope Für Pen is a recombinant form of human growth hormone that binds to growth‑hormone receptors on target cells. Receptor activation triggers the JAK2‑STAT5 signaling cascade, leading to increased transcription of insulin‑like growth factor‑1 (IGF‑1) in the liver and peripheral tissues. Elevated IGF‑1 mediates anabolic effects on bone, muscle, and cartilage, promoting protein synthesis, cell proliferation, and linear growth. The hormone also influences lipid metabolism and glucose homeostasis through secondary pathways.

Adverse reactions to Humatrope Für Pen are reported in clinical use and may vary in frequency and severity.

Common

• Injection site pain or erythema
• Headache
• Transient edema of the limbs
• Joint stiffness or arthralgia
• Nausea or abdominal discomfort
• Flu‑like symptoms
• Muscle cramps
• Fatigue
• Dizziness

Serious

• Intracranial hypertension presenting with headache and visual changes
• Hyperglycemia or new‑onset diabetes mellitus
• Severe allergic reactions including anaphylaxis
• Slipped capital femoral epiphysis in growing children
• Cardiomyopathy or worsening heart failure
• Pancreatitis
• Severe hypoglycemia

Before initiating therapy with Humatrope Für Pen, clinicians should evaluate patients for conditions that may increase the risk of adverse events or affect treatment outcomes.

• Assess for active malignancy, as growth hormone may stimulate tumor growth.
• Screen for uncontrolled diabetes or impaired glucose tolerance.
• Evaluate for intracranial hypertension or a history of pseudotumor cerebri.
• Review any prior hypersensitivity reactions to somatropin or device components.
• Monitor thyroid function, especially in patients with pituitary disease.
• Use caution in patients with severe renal or hepatic impairment.
• Discuss potential impact on bone development in pediatric patients.

Humatrope Für Pen may interact with other medicines or substances that alter its efficacy or increase the likelihood of side effects.

Avoid

• Concurrent use of high‑dose glucocorticoids, which can antagonize growth‑hormone effects.
• Long‑acting insulin analogues without close glucose monitoring, risking severe hyperglycemia.
• Medications that increase intracranial pressure, such as tetracyclines or vitamin A excess.

Use with caution

• Oral estrogen therapy, which may reduce IGF‑1 response.
• Antidiabetic agents, requiring adjustment of blood‑glucose monitoring.
• Thyroid hormone replacement, as thyroid status influences growth‑hormone action.
• Loop diuretics, which can affect fluid balance and edema risk.